Ribavirin-pegylated interferon alfa hcv combination therapy

Details Ribavirin-pegylated interferon alfa hcv combination therapy Ribavirin-pegylated interferon alfa hcv combination therapy

A - Human Necessities

61

K

A61K 38/21 (2006.01) A61K 31/7056 (2006.01) A61K 45/06 (2006.01) A61P 31/12 (2006.01)

Patent

CA 2425522

The use of ribavirin and/or pegylated interferon alfa for the preparation of a pharmaceutical composition for the treatment of chronic hepatitis C infection comprising a therapeutically weight-effective amount of ribavirin and a therapeutically effective amount of pegylated, e.g, pegylated interferon-alfa- 2b or -2a, is disclosed.

L'invention porte sur l'utilisation de la ribavirine et/ou de l'interféron alpha pégylé dans la préparation d'une composition pharmaceutique destinée au traitement de l'infection chronique par le virus de l'hépatite C. Ladite composition comprend une quantité de ribavirine, thérapeutiquement efficace en fonction du poids du patient, et d'une quantité thérapeutiquement efficace d'interféron pégylé, tel que l'interféron alpha 2b ou 2a pégylé.

Affiliated with

Also associated with

Rating

Ribavirin-pegylated interferon alfa hcv combination therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ribavirin-pegylated interferon alfa hcv combination therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ribavirin-pegylated interferon alfa hcv combination therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1415741